Table 2.
Stratification in ranges: <20 ng/mL, sub-therapeutic; 20–60 ng/mL, therapeutic range; >60, supra-therapeutic.
| Number of Samples (%) | Statistics | |||||||
|---|---|---|---|---|---|---|---|---|
| Alinity C | Cohen’s Weighted Kappa | |||||||
| Active Moiety | <20 ng/mL | 20–60 ng/mL | >60 ng/mL | Total | K | SE | CI 95% | |
| UHPLC-MS/MS | <20 ng/mL | 8 (8.7) | 5 (5.43) | 0 | 13 | 0.72 | 0.06 | 0.58–0.95 |
| 20–60 ng/mL | 2 (2.17) | 51 (55.43) | 5 (5.43) | 58 | McNemar test | |||
| >60 ng/mL | 0 | 3 (3.26) | 18 (19.57) | 21 | (<20 ng/mL)–(20–60 ng/mL) | (20–60 ng/mL)–(>60 ng/mL) | ||
| Total | 10 | 59 | 23 | 92 | p-value = 0.45 | p-value = 0.72 | ||